Prioritisation of potentially obsolete technologies

Similar documents
HTA, the roadmap from investment to disinvestment

Andalusian Agency for Health Technology Assessment (AETSA)

Decision Determinants Guidance Document

European Network for Health Technology Assessment (EUnetHTA) Joint Action 3

ABHI Response to the Kennedy short study on Valuing Innovation

SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM. New ideas & Improvements

WHO Workshop, Bangkok, Health Technology Assessment

Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:

Health Technology Assessment and the European Network for HTA

SHTG primary submission process

Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy)

How can value be measured and assessed?

Towards a Magna Carta for Data

Horizon Scanning. Why & how to launch it in Lithuania? Prof. Dr. Rafael Popper

Key Issues for Successful E-Health Solutions

Reduce cost sharing and fees Include other services. Services: which services are covered? Population: who is covered?

25 th Workshop of the EURORDIS Round Table of Companies (ERTC)

13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer

Finn Børlum Kristensen, MD, PhD Director, EUnetHTA Secretariat Danish Health and Medicines Authority (EUnetHTA Coordinator) Copenhagen, Denmark

Primary IVF Conditions for Registration For Assisted Reproductive Treatment Providers under the Assisted Reproductive Treatment Act 2008

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

Policies for the Commissioning of Health and Healthcare

December Eucomed HTA Position Paper UK support from ABHI

Use of the Graded Approach in Regulation

Adaptation of HTA reports: an effective way to use limited resources?

CADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes

INFORMATION FOR RELATIVES

Counterfeit, Falsified and Substandard Medicines

clarification to bring legal certainty to these issues have been voiced in various position papers and statements.

WHO/PRP/11.1 ENGLISH ONLY MEDIUM-TERM STRATEGIC PLAN INTERIM ASSESSMENT

Vincent RIALLE. Maître de conférences-praticien hospitalier, Dr GBM, Dr éthique médicale et biologique

Draft Plan of Action Chair's Text Status 3 May 2008

NHS South Tees Clinical Commissioning Group. Governing Body. Agenda Item:

B) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:

WANT TO PARTICIPATE IN RESEARCH? THERE S AN APP FOR THAT!

Assessment element tables

Medical Education Activities

Advancing Health and Prosperity. A Brief to the Advisory Panel on Healthcare Innovation

Cheshire, Warrington and Wirral Area Team Commissioning for Value Pack

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)

Early HTA to inform value driven market access and reimbursement planning

Notice to The Individual Signing The Power of Attorney for Health Care

TOWARD TRANSPARENCY IN HEALTH TECHNOLOGY ASSESSMENT

e-care Living Lab - 5 avenue du Grand Sablon La Tronche - FRANCE Tel: +33 (0)

Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI

An Evaluation Framework. Based on the slides available at book.com

Medical Technology Association of NZ. Proposed European Union/New Zealand Free Trade Agreement. Submission to Ministry of Foreign Affairs & Trade

Notice of Privacy Practices

Why do so many technology programmes in health and social care fail?

Roche Pharma Report Relating to EUnetHTA HTA Core Model Applications for Pharmaceuticals. December 21 st 2014

About Advance Directives for Mental Health

Tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases

g~:~: P Holdren ~\k, rjj/1~

Coordinate finger jointer operations in solid wood manufacturing

Clinical Commissioning Groups HR Frequently Asked Questions (FAQs)

Safety and Security. Pieter van Gelder. KIVI Jaarccongres 30 November 2016

Human Biological Material Collection, Storage and Use

Paola Bailey, PsyD Licensed Clinical Psychologist PSY# 25263

A/AC.105/C.1/2006/NPS/CRP.7 16 February 2006

Supporting medical technology development with the analytic hierarchy process Hummel, Janna Marchien

'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint

EU s Innovative Medical Technology and EMA s Measures

SMA Europe Code of Practice on Relationships with the Pharmaceutical Industry

UNIVERSITY OF ZAGREB SCHOOL OF MEDICINE. Plan of the course. Epidemiology. Academic year 2015/2016. izv. prof. dr. sc.

Health Technology Assessment (HTA) Dr Hamid Ravaghi

City and Hackney CCG Clinical Governance Framework. Approved by the CCG Board November 2014

ROCKY MOUNTAIN RAPTOR PROGRAM Volunteer Application. Rodent Wrangler

Medicaid Managed Care Grievance Procedures

Research with Digital Health Methods 2.0 version date: 03/06/18

Human Factors Points to Consider for IDE Devices

Planning for the Future: The Role of Advance Directives

Global Perspectives on Clinical Engineering Trends Yadin David, Ed.D., P.E., C.C.E., FAACE, FAIMBE

Christina Narensky, Psy.D.

Effective early warning systems for new and emerging health technologies: Developing an evaluation framework and an assessment of current systems

IHT at the HTAi A parallel workshop June 2005 Rome. Introduction Andrew Webster Programme Director

Webinar IMI2 - Call 15 Digital endpoints in neurodegenerative and immunemediated

E5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006

EU Cooperation on Health Technology Assessment

TOOL #21. RESEARCH & INNOVATION

Violent Intent Modeling System

IoT in Health and Social Care

ISO/IEC INTERNATIONAL STANDARD. Information technology Security techniques Privacy framework

Draft global strategy on public health, innovation and intellectual property

Bringing Technology and Product Development Best Practices Together for Successful Innovation

Health Technology Assessment of innovative medical devices

NHS CONTINUING HEALTH CARE:

NCRIS Capability 5.7: Population Health and Clinical Data Linkage

When Must a Non-UH Investigator Seek Review by the UH IRB? the Issue of Engagement

SUMMARY EDITORIAL PULSE PLATFORM COMPONENTS. PULSE Newsletter. Editorial and Platform Components

CCG 360 o stakeholder survey 2017/18

Global strategy and plan of action on public health, innovation and intellectual property

Table Of Content. Stichting Health Action International... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs...

Ministry of Justice: Call for Evidence on EU Data Protection Proposals

SAFEGUARDING ADULTS FRAMEWORK. Prevention and effective responses to neglect, harm and abuse is a basic requirement of modern health care services.

Justice Select Committee: Inquiry on EU Data Protection Framework Proposals

Elements of a global strategy and plan of action

EMA experience with the review of digital technology proposals in medicine development programmes

Extract of Advance copy of the Report of the International Conference on Chemicals Management on the work of its second session

ENCePP Work Plan

Transcription:

Maximising the value of HTA. Closing the loop of the life cycle of technologies. Assessing low added value technologies. Prioritisation of potentially obsolete technologies Prof Alberto Ruano-Ravina, L Varela-Lema, T Cerdá Mota, et al. Galician Agency of Health Technology Assessment (avalia-t)

Agenda Why to prioritize obsolete technologies? How to prioritize obsolete technologies? Exercise Practical tools, the PriTec software Conclusions

Why to prioritize? - Too many obsolete technologies are being currently used in clinical practice. - Only those generating a large impact in health care merit attention Prioritisation criteria. - Provide transparence when deciding which one has to be assessed. - Limited resources of assessment bodies.

How to prioritize? Establishing prioritisation criteria Who should establish these criteria? Researchers from health technology assessment agencies? Clinicians? Health managers? Patients? Should they agree with the others criteria? Why not join their opinions and compare if they differ?

How to prioritize? Establishing prioritisation criteria Implicit criteria are: Effectiveness Safety Cost-effectiveness Organizational issues Patients and clinicians preferences Frequency of use of the obsolete technology Ethical, social aspects

How to prioritize? Establishing prioritisation criteria and weighting Population/users (weighting 36.7%) Frequency of the disease Burden of disease Frequency of use of the obsolete technology Patients preferences Risk/benefit ratio (36.7%) Efficacy/effectiveness/reliability Adverse effects Risks (definition) Costs, organization and other implications (26.6%) Efficiency Mainteinance costs Other implications 11 clinicians, 12 health managers and 6 patients

Exercise Read carefully the instructions provided and the outline of the three potentially obsolete technologies. Form groups of 5-6 people and give a consensus scoring to each technology. Write down the scoring in the provided prioritization sheet. You have 15 minutes.

Exercise Prioritisation scoring for each technology given by two groups. Discussion on discrepancies is not allowed (time schedule reasons).

Population/end-user domain of prioritisation tool. RX Surg Est Disease frequency The condition or indication for which the potentially obsolete technology can be used is frequent (high prevalence and/or incidence). Disease burden The condition or indication for which the potentially obsolete technology can be used amounts to a considerable health loss for the patient (mortality, morbidity, disability). Frequency of use of technology The potentially obsolete technology is currently applied to a high number of patients. There is scientific evidence of a lower acceptance by patients of the potentially obsolete technology versus other existing technological alternatives (e.g., greater unpleasantness, greater discomfort, longer Patient preferences treatments). Risk/benefit domain of prioritisation tool. RX Surg Est Efficacy/Effectiveness/Va lidity Adverse effects The scientific literature indicates that the potentially obsolete technology displays less efficacy or effectiveness than other alternative technologies. If it is a diagnostic technology, the potentially obsolete diagnostic test is less valid (yields more false positives and negatives than other available diagnostic tests). There is evidence in the literature of more adverse or more important effects with the potentially obsolete technology versus other existing technological alternatives. The potentially obsolete technology poses a higher likelihood of health-care staff falling ill or having a work accident (e.g., radiations) or of a greater environmental hazard (e.g., waste) than do other existing Risks technological alternatives. Costs domain, organisation and other implications of the prioritisation tool. RX Surg Est Efficiency There are financial evaluation studies that are more favourable for other existing technological alternatives. Maintenance costs Other implications The potentially obsolete technology requires more resources for its functioning (e.g., consumables, reviews, human resources, etc.) versus other existing technological alternatives. It is foreseeable that withdrawal of the potentially obsolete technology will have a positive impact on the ethical, cultural and/or legal sphere.

Prioriticising. The PriTec tool www.pritectools.com www.pritectools.es

Conclusions Is PriTec a friendly tool to prioritise obsolete health technologies? Is PriTec potentially reliable when used by different people? And if used by people with different background? Does PriTec allow for the priotirisation of technologies through using homogeneus, sound and explicit criteria? Is PriTec applicable to different health care settings? Can PriTec qualify different technologies with a quantitative result in an objective way? Do the participation of the interested parties in the ellaboration of the tool enable a high external validity?